A private equity firm based in Paris, France has €400M AUM and looks to invest in venture stages in the life sciences – seed to later phases. The firm mainly provides equity financing and may provide convertible loans as follow-on investments. The firm typically makes an initial investment of €2-3M and €5-8M over the life of the investment. The firm only invests in European-based companies. The firm is actively seeking new investment opportunities.

The firm is opportunistic in the life sciences. The firm focuses on drug development, diagnostics, and medical devices.  The firm is agnostic in terms of subsectors and indications. The firm prefers companies with a portfolio of 2-3 products. The firm generally looks for therapeutic companies with products that are in the pre to late clinical phases. Currently, the firm is active in many subsectors including therapeutics that addresses autoimmune, inflammatory diseases, cancer, diabetes, Alzheimer’s disease, pulmonary devices and cardiac devices.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A healthcare investment firm that was founded in 2007 and based in The Netherlands has raised two funds, with the most recent fund closing in 2012. The firm seeks to make equity investments into Dutch technology-driven healthcare companies. The investment size typically ranges from € 0.1 million to € 0.4 million, and it can go up to € 2 million with consortium over the life of an investment. The firm is looking to make at least 7 investments in the next 2-3 years. The firm focuses on companies that are based in The Netherlands.

In the Life Sciences space, the firm is currently seeking new investments in the Medical Technology, R&D Services and Healthcare IT sectors. The firm looks for all classes of medical devices and is opportunistic in terms of indications; however, the firm is most interested in companies developing innovative technologies that have impacts on healthcare processes and/or have impacts on the patients. The firm has a market focus instead of a technology focus. The firm generally invests in companies in the market introduction Phase, but it can also invest earlier-stage companies that have great impacts on healthcare.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A Canadian VC firm is currently investing from a second fund raised in 2014, with a closing target of $150 million.  The fund will make equity investments in early-stage life science companies based in Canada and the USA.  The firm prefers to lead or co-lead investments.  Initial investments will typically be of about $5 million, with capital reserved for potential follow-on investments of up to $15 million total per opportunity.  The firm is likely to make 10-12 investments over the fund’s lifetime.

The firm will make about 75% of its allocations in the therapeutics sector, with the remainder invested in diagnostics, medical devices, and/or tools or healthcare IT.  The firm prefers to invest in early-stage opportunities; in the therapeutics sector, investments may be made in companies with a lead product 12-18 months prior to IND.  The fund is generally agnostic in terms of technological field and indication area, but is less likely to invest in products targeting CNS disorders and pain.

The firm only invests in those therapeutic companies that have identified a lead product candidate.  About two-thirds of investments will be made in Canada-based life science companies, with half of the Canadian portfolio consisting of Quebec-based companies; the remaining one-third of the fund will be invested in USA-based companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

An evergreen fund that was established in 2013 and is based in Taiwan is operating from a committed capital of USD 300 million. The fund makes equity investments in early- to late-stage private businesses in the life science space. Typical allocations range from USD 1.5 million to north of USD 10 million. The fund likes to lead investments in Taiwan-based businesses and co-invest in businesses overseas. The fund is currently seeking new opportunities in Taiwan, Greater China, Southeast Asia, US, Canada, and EU.

The fund takes a generalist approach when considering life science opportunities, including therapeutics (small molecule and biologics), medical devices, diagnostics, healthcare services, and nutraceuticals. The fund is seeking cutting edge, innovative, and platform technology. In therapeutics, the fund considers all stages from preclinical through pre-IPO. In medical devices, the fund prefers later stage projects with proof of concept. The fund is open to all disease indications.

The fund is looking for competent, experienced, and reliable management teams when considering investment. Prior to deciding on allocations, the fund’s management team typically spends months interacting with candidate companies to determine their track record, quality of scientific research, technical expertise, and flexibility and reliability in working with investors. The fund typically requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A family of private equity funds, which has two US-based offices in, and one operation in Beijing, China is currently looking to make investments in all major areas of the healthcare industry. The firm typically provides equity and equity-related capital to small and emerging healthcare companies at late-clinical stage and commercial stage. The investment size will vary, depending on the opportunity. The firm will consider investment opportunities across the globe with a focus in the US and Asia.

The firm is currently looking for new opportunities in the Therapeutics. Diagnostics, Medical device, Biotech service, Healthcare IT and other healthcare companies. For therapeutics, the firm will invest in both small molecules and biologics, and it typically looks for emerging biopharmaceutical companies with assets later than Phase II. In the medtech sector, the firm will consider all classes of medical devices. The firm generally invests in commercial products and development stage companies that have passed key milestones. Historically, the firm was active in a molecular diagnostics laboratory, medical device companies, healthcare IT companies and biopharmaceutical companies.

The firm focuses on privately held companies that have already established operations or have completed a substantial portion of their development process for new products, technologies and services. The firm looks to take a board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A single family office and advisory firm based in the Western United States is looking to make allocations in the life science space. Typical investments are north of $5 million although due to the firm capital structure they can be flexible. The firm is currently seeking new investment opportunities in the US and China.

In life sciences the firm is a generalist in terms of technology sectors including biotech therapeutics, diagnostics and medical devices. That being said, the firm has a special interest in regenerative medicine. The firm prefers to work with pre-IPO life science companies and was recently involved in a round for a company developing orthobiologic products.

The firm is looking for experienced management teams and generally requires a board seat in the companies it invests in.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large tech company is actively seeking investments in the life science space. The firm manages two venture funds worth a total of $1.1B; focus on early-stage companies; target companies of all sizes respectively.  The firm is actively seeking new investment opportunities and is open to review opportunities from around the globe.

In the Life Sciences, the firm seeks to invest in Mobile healthcare IT, bio authentication, fitness and wellness measurement algorithm (i.e. Fitbit and Basis type of companies), calorie measurement, heart measurement, glucose measurement, and medical imaging equipment technology (i.e. Ultrasound, MRI, CAT scan, and image enhancement and distribution tech). The firm is open to reviewing companies of all stages.

The firm is looking for companies with experienced management teams and generally looks to take a board seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com